Retinal Vein Occlusion care is entering a new era-where science meets patient convenience. The shift toward longer-acting, multi-targeted, safer therapies will redefine outcomes and access.” ...

The FDA has granted Priority Review status to Regeneron’s and Bayer’s supplemental Biologics License Application (sBLA) for Eylea HD (aflibercept) injection 8 mg. The application seeks to expand use ...

The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for aflibercept injection 8mg for the treatment of macular edema ...

The global retinal vein occlusion market is experiencing significant growth, driven by advancements in treatment options such as anti-VEGF therapies and laser procedures. Increasing healthcare ...

The global retinal vein occlusion (RVO) market, valued at US$ 2.8 billion in 2023, is poised for substantial growth over the next decade. With a projected compound annual growth rate (CAGR) of 6.7% ...

Central retinal vein occlusion, or CRVO, occurs when the main, or central, vein becomes blocked. Central retinal vein occlusion can happen quickly, triggering sudden vision loss.

Why these recommendations were made Visual impairment caused by macular oedema after retinal vein occlusion is usually treated with an anti-vascular endothelial growth factor (anti‑VEGF) treatment ...

Central Retinal Vein Occlusion affects between 1 and 4 per 1,000 people, while Branch Retinal Vein Occlusion is more common, affecting between 6 and 12 per 1,000 people.

Retinal vein occlusion (RVO) is a significant retinal vascular disorder that can lead to severe visual impairment. Recent research suggests that vitamin D may play a crucial role in preventing and ...

Branch retinal vein occlusion (BRVO) is when a blockage forms in the veins branching off the retina, which can disrupt blood flow. Treatment depends on the type of blockage and severity of the damage.

Current treatments for RVO are given every one to two months; the Vabysmo studies administered six monthly treatments over the first 20 weeks, then up to every four months from weeks 24 to 72 (1).

Central retinal vein occlusion (CRVO) is an eye condition that affects a vein in the retina. Learn about symptoms, causes, treatments, and more.